{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:04:32Z","timestamp":1793898272158,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To determine the safety and efficacy of biological agents used in the treatment of systemic lupus erythematosus (SLE) in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis following PRISMA guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>MEDLINE (through Pubmed), EMBASE, Cochrane library, Clinicaltrials.gov, Australianclinicaltrials.gov.au, ANZCTR.org.au and WHO International Clinical Trials Registry Platform for studies published from 20 May 2021 and 15\u00a0years prior. A grey literature search was performed and completed on 31 May 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study criteria<\/jats:title>\n                    <jats:p>Phase II, III or quasi randomised controlled trials, studies with only cerebral or cutaneous lupus were excluded. Data extraction: Two authors independently screened studies for eligibility, extracted, reviewed data for accuracy, and used the Cochrane tool to assess risk of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-four studies were identified, consisting of 15 groups of drugs and 25 different biological agents, totalling 16,889 patients. The main outcomes assessed included Systemic Lupus Erythematosus Responder Index (SRI), BILAG-Based Composite Lupus Assessment (BICLA) and combined combined\/partial renal remission (CRR\/PRR).<\/jats:p>\n                    <jats:p>Four groups of biologics were found to improve outcomes. Anti-interferons: Anifrolumab increased BICLA response and SRI 5 to 8, decreased prednisone dosages, with increased herpes zoster infections, but fewer serious adverse events. Sifalimumab improved SRI but also increased herpes zoster infections. Anti BAFF\/BLyS and\/or APRIL: Belimumab consistently improved SRI 4, decreased prednisone dosages, increased combined CRR\/PRR, and had no adverse safety outcomes. Tabalumab increased SRI 5 at 52\u00a0weeks with no steroid sparing effect but was associated with increased infusion related adverse events. Telitacicept improved SRI 4 at 52\u00a0weeks, with no increased adverse events, though data was rather sparse. Anti CD-20 monoclonal antibody, Obinutuzumab increased combined CRR\/PRR at 1 and 2\u00a0years. Anti IL12\/23 monoclonal antibody, Ustekinumab, increased SRI 4 to 6, but not BICLA at 24\u00a0weeks, with no concerning safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Multiple biologic agents are shown in high quality studies to have a significant therapeutic impact on outcomes in SLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-023-00358-3","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T03:56:21Z","timestamp":1696823781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-1749","authenticated-orcid":false,"given":"Justin","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles D.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prianka","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon H.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"358_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20\u20138.","journal-title":"Ann Rheum Dis"},{"key":"358_CR2","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/art.27601","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:3077\u201387.","journal-title":"Arthritis Rheum"},{"key":"358_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/art.38260","volume":"66","author":"R Furie","year":"2014","unstructured":"Furie R, Nicholls K, Cheng T-T, et al. Efficacy and safety of Abatacept in lupus nephritis: a twelve-month, randomized, double-blind study: Abatacept in lupus nephritis. Arthritis Rheumatol. 2014;66:379\u201389.","journal-title":"Arthritis Rheumatol"},{"key":"358_CR4","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38790","volume":"66","author":"The ACCESS Trial Group","year":"2014","unstructured":"The ACCESS Trial Group. Treatment of lupus nephritis with Abatacept: the Abatacept and cyclophosphamide combination efficacy and safety study: Abatacept in lupus nephritis. Arthritis Rheumatol. 2014;66:3096\u2013104.","journal-title":"Arthritis Rheumatol"},{"key":"358_CR5","first-page":"176","volume":"77","author":"R Furie","year":"2018","unstructured":"Furie R, Dooley MA, Wofsy D, et al. OP0253 A phase iii randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class iii or iv lupus nephritis. Ann Rheum Dis. 2018;77:176\u20137.","journal-title":"Ann Rheum Dis"},{"key":"358_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-\u03b1 Receptor Monoclonal Antibody, in moderate-to-severe systemic lupus erythematosus: Anifrolumab in moderate-to-severe SLE. Arthritis Rheumatol. 2017;69:376\u201386.","journal-title":"Arthritis Rheumatol"},{"key":"358_CR7","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208\u201319.","journal-title":"Lancet Rheumatol"},{"key":"358_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211\u201321.","journal-title":"N Engl J Med"},{"key":"358_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","volume":"75","author":"KC Kalunian","year":"2016","unstructured":"Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75:196\u2013202.","journal-title":"Ann Rheum Dis"},{"key":"358_CR10","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","volume":"75","author":"M Khamashta","year":"2016","unstructured":"Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1909\u201316.","journal-title":"Ann Rheum Dis"},{"key":"358_CR11","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/art.24699","volume":"61","author":"DJ Wallace","year":"2009","unstructured":"Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res. 2009;61:1168\u201378.","journal-title":"Arthritis Care Res"},{"key":"358_CR12","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of Belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918\u201330.","journal-title":"Arthritis Rheum"},{"key":"358_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al. Efficacy and safety of Belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721\u201331.","journal-title":"Lancet"},{"key":"358_CR14","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous Belimumab in systemic lupus erythematosus: a fifty-two\u2013week randomized, double-blind placebo-controlled study. Arthritis Rheumatol. 2017;69:1016\u201327.","journal-title":"Arthritis Rheumatol"},{"key":"358_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","volume":"77","author":"F Zhang","year":"2018","unstructured":"Zhang F, Bae S-C, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355\u201363.","journal-title":"Ann Rheum Dis"},{"key":"358_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of Belimumab in lupus nephritis. N Engl J Med. 2020;383:1117\u201328.","journal-title":"N Engl J Med"},{"key":"358_CR17","doi-asserted-by":"publisher","unstructured":"Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol Hoboken NJ. https:\/\/doi.org\/10.1002\/art.41466. Epub ahead of print 4 August 2020.","DOI":"10.1002\/art.41466"},{"key":"358_CR18","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","volume":"74","author":"RA Furie","year":"2015","unstructured":"Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74:1667\u201375.","journal-title":"Ann Rheum Dis"},{"key":"358_CR19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","volume":"77","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77:883\u20139.","journal-title":"Ann Rheum Dis"},{"key":"358_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","volume":"75","author":"DA Isenberg","year":"2016","unstructured":"Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:323\u201331.","journal-title":"Ann Rheum Dis"},{"key":"358_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"JT Merrill","year":"2016","unstructured":"Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:332\u201340.","journal-title":"Ann Rheum Dis"},{"key":"358_CR22","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74:2006\u201315.","journal-title":"Ann Rheum Dis"},{"key":"358_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of Atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm Phase IIb Study. Arthritis Rheumatol. 2018;70:266\u201376.","journal-title":"Arthritis Rheumatol"},{"key":"358_CR24","unstructured":"RemeGen Co., Ltd. A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy. 2021. Clinical Trial Registration NCT04905212, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04905212. Accessed 1 Nov 2021."},{"key":"358_CR25","unstructured":"A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis. ACR Meeting Abstracts, https:\/\/acrabstracts.org\/abstract\/a-phase-ii-randomized-double-blind-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-obinutuzumab-or-placebo-in-combination-with-mycophenolate-mofetil-in-patients-with-active-class-iii\/. Accessed 27 Aug 2021."},{"key":"358_CR26","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","volume":"65","author":"EF Mysler","year":"2013","unstructured":"Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of Ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study: Ocrelizumab in lupus nephritis. Arthritis Rheum. 2013;65:2368\u201379.","journal-title":"Arthritis Rheum"},{"key":"358_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii\/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222\u201333.","journal-title":"Arthritis Rheum"},{"key":"358_CR28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64:1215\u201326.","journal-title":"Arthritis Rheum"},{"key":"358_CR29","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","volume":"392","author":"RF van Vollenhoven","year":"2018","unstructured":"van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet Lond Engl. 2018;392:1330\u20139.","journal-title":"Lancet Lond Engl"},{"key":"358_CR30","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1002\/art.23673","volume":"58","author":"MH Cardiel","year":"2008","unstructured":"Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008;58:2470\u201380.","journal-title":"Arthritis Rheum"},{"key":"358_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 2018;392:222\u201331.","journal-title":"The Lancet"},{"key":"358_CR32","doi-asserted-by":"publisher","unstructured":"Wallace DJ, Martin EC, Ona V, et al. 212 Phase 2, randomized, double-blind, placebo-controlled, dose-finding study, evaluating the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in patients with systemic lupus erythematosus: study design. Lupus Sci Med. 6. https:\/\/doi.org\/10.1136\/lupus-2019-lsm.212. Epub ahead of print 1 April 2019.","DOI":"10.1136\/lupus-2019-lsm.212"},{"key":"358_CR33","doi-asserted-by":"publisher","unstructured":"Isenberg D, Furie R, Jones NS, et al. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton\u2019s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Systemic Lupus Erythematosus. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41811.","DOI":"10.1002\/art.41811"},{"key":"358_CR34","doi-asserted-by":"publisher","unstructured":"Gaudy A, Ye Y, Korish S, et al. SAT0225 Cereblon modulator CC-220 decreases na\u00cfve and memory B cells and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients: exposure-response results from a phase 2A proof of concept study. In: Poster Presentations. BMJ Publishing Group Ltd and European League Against Rheumatism, p. 858.2\u2013859. https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.3036.","DOI":"10.1136\/annrheumdis-2017-eular.3036"},{"key":"358_CR35","unstructured":"Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study - ACR Meeting Abstracts, https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-iberdomide-in-patients-with-active-systemic-lupus-erythematosus-24-week-results-of-a-phase-2-randomized-placebo-controlled-study\/. Accessed 27 Aug 2021."},{"key":"358_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000104","volume":"2","author":"MB Urowitz","year":"2015","unstructured":"Urowitz MB, Isenberg DA, Wallace DJ. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Sci Med. 2015;2: e000104.","journal-title":"Lupus Sci Med"},{"key":"358_CR37","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","volume":"52","author":"DJ Wallace","year":"2013","unstructured":"Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology. 2013;52:1313\u201322.","journal-title":"Rheumatology"},{"key":"358_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","volume":"73","author":"DJ Wallace","year":"2014","unstructured":"Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73:183\u201390.","journal-title":"Ann Rheum Dis"},{"key":"358_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","volume":"69","author":"MEB Clowse","year":"2017","unstructured":"Clowse MEB, Wallace DJ, Furie RA, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials: efficacy and safety of Epratuzumab in SLE. Arthritis Rheumatol. 2017;69:362\u201375.","journal-title":"Arthritis Rheumatol"},{"key":"358_CR40","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","volume":"76","author":"DJ Wallace","year":"2017","unstructured":"Wallace DJ, Strand V, Merrill JT, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017;76:534\u201342.","journal-title":"Ann Rheum Dis"},{"key":"358_CR41","unstructured":"Ablynx. A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus. 2019. Clinical Trial Registration NCT02437890, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02437890. Accessed 15 June 2021."},{"key":"358_CR42","unstructured":"Biotest. A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus. 2020. Clinical Trial Registration study\/NCT02554019, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02554019. Accessed 15 June 2021."},{"key":"358_CR43","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1136\/annrheumdis-2012-202460","volume":"72","author":"R Zimmer","year":"2013","unstructured":"Zimmer R, Scherbarth HR, Rillo OL, et al. Lupuzor\/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013;72:1830\u20135.","journal-title":"Ann Rheum Dis"},{"key":"358_CR44","unstructured":"Tillmanns S. SM101, a Novel Recombinant, Soluble, Human Fc\u03b3IIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study. ACR Meeting Abstracts, https:\/\/acrabstracts.org\/abstract\/sm101-a-novel-recombinant-soluble-human-fc\u03b3iib-receptor-in-the-treatment-of-systemic-lupus-erythematosus-results-of-a-double-blind-placebo-controlled-multicenter-study\/. Accessed 28 Aug 2021."},{"key":"358_CR45","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1136\/ard-2022-222858","volume":"81","author":"RF van Vollenhoven","year":"2022","unstructured":"van Vollenhoven RF, Kalunian KC, D\u00f6rner T, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. 2022;81:1556\u201363.","journal-title":"Ann Rheum Dis"},{"key":"358_CR46","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397:2070\u201380.","journal-title":"Lancet"},{"key":"358_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/14397595.2020.1775928","volume":"31","author":"K Ohmura","year":"2021","unstructured":"Ohmura K. Which is the best SLE activity index for clinical trials? Mod Rheumatol. 2021;31:20\u20138.","journal-title":"Mod Rheumatol"},{"key":"358_CR48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.semarthrit.2018.01.001","volume":"48","author":"S Oon","year":"2018","unstructured":"Oon S, Huq M, Godfrey T, et al. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Semin Arthritis Rheum. 2018;48:221\u201339.","journal-title":"Semin Arthritis Rheum"},{"key":"358_CR49","first-page":"211","volume":"28","author":"HHL Borba","year":"2014","unstructured":"Borba HHL, Wiens A, de Souza TT, et al. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. BioDrugs Clin Immunother Biopharm Gene Ther. 2014;28:211\u201328.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"358_CR50","doi-asserted-by":"publisher","unstructured":"Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD010668.pub2. Epub ahead of print 2021.","DOI":"10.1002\/14651858.CD010668.pub2"},{"key":"358_CR51","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.autrev.2017.01.010","volume":"16","author":"S Sciascia","year":"2017","unstructured":"Sciascia S, Radin M, Yazdany J, et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. Autoimmun Rev. 2017;16:287\u201393.","journal-title":"Autoimmun Rev"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-023-00358-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-023-00358-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-023-00358-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T13:01:36Z","timestamp":1700398896000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-023-00358-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1186\/s41927-023-00358-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2774547\/v1","asserted-by":"object"}]},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"4 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}